Primary liver cancer
Conditions
Interventions
Control group:Carry out standardized Western medical treatment in accordance with the "Diagnosis and Treatment Specifications for Primary Liver Cancer" (2017 Edition)
Treatment group:According to the "Diagnosis and Treatment Guidelines for Primary Liver Cancer" (2017 Edition), receive standardized Western medical treatment, and add the treatment with Heshu Xiaoji P
Sponsors
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients who meet the diagnostic criteria for primary liver cancer as stipulated in the "Diagnosis and Treatment Specifications for Primary Liver Cancer (2022 Edition)", and have received standardized treatment for primary liver cancer; 2) Age between 18 and 75 years old; 3) No severe disorders in heart, liver and kidney functions; 4) Patients with liver function classified as Child-Pugh A or B grade; 5) Expected survival period of = 3 months; 6) Voluntarily signed informed consent form.
Exclusion criteria
Exclusion criteria: 1) Those with other tumor diseases; 2) Those with severe primary diseases such as cardiovascular and cerebrovascular diseases, kidney diseases, and hematological diseases; 3) Pregnant or lactating women; 4) Those with mental disorders, meeting the criteria of the Chinese Classification and Diagnosis of Mental Disorders (CCMD-3); 5) Patients with allergic constitution or known allergies to certain components of traditional Chinese medicine; 6) Those with a history of drug abuse or addiction; 7) Those with severe liver function damage, severe jaundice, ascites, severe infection that cannot be corrected; 8) KPS = 30 points; 9) Patients whose compliance was checked and could not follow up on time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver injury condition: enzymatic indicators (ALT, AST, GGT), bilirubin (TBIL, DBIL), albumin (ALB), coagulation function (PT, INR), Child-Pugh score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor markers: Abnormal prothrombin (PIVKAII), Alpha-fetoprotein (AFP);Incidence of adverse reactions related to standardized treatment: symptoms such as fever, pain, abdominal distension, nausea and vomiting, and rash;Physical fitness score and quality of life score of cancer patients; | — |
Countries
China
Contacts
Public ContactWang Jing
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Outcome results
None listed